September 16, 2024 04:25 AM EDTUpdated 06:37 AM
R&D
Pharma
Coronavirus

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Ryan Cross

Senior Science Correspondent

The mR­NA-based Covid vac­cines used by hun­dreds of mil­lions of peo­ple may pro­vide an un­ex­pect­ed ben­e­fit to some can­cer pa­tients, sig­nif­i­cant­ly im­prov­ing sur­vival when giv­en …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The brain is Eli Lil­ly's next tar­get for its obe­si­ty meds

The End­points 100: The biotech in­dus­try braces for Trump 2.0

Dur­ing Covid, RFK Jr. lob­bied against vac­cine EUAs for chil­dren. As HHS sec­re­tary, he could re­scind them

Can­del’s shares soar on Phase 3 prostate can­cer da­ta de­spite un­clear prospects

Gene edit­ing com­pa­nies seek safer, less gru­el­ing con­di­tion­ing meth­ods for blood stem cell ther­a­pies

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times